BioPharmSignal logoBioPharmSignal

Biotech News

Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results

Pulse Biosciences (PLSE)Pulse BiosciencesEarnings

HAYWARD, Calif. --(BUSINESS WIRE)--Aug. 6, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced business updates and financial results for the second quarter ended June 30,

Related news

PLSEPulse Biosciences2026-07-21 20:05 EST

Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026

ACHCAcadia Healthcare2026-07-28 20:05 EST

Acadia Healthcare Announces Second Quarter 2026 Results and Updates Full Year 2026 Financial and Cash Flow Guidance

RXSTRxSight2026-07-06 20:15 EST

RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement

CVRXCVRx2026-08-06 20:05 EST

CVRx Reports Second Quarter 2026 Financial and Operating Results

ICUIICU Medical2026-08-06 20:05 EST

ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance

MMSIMerit Medical2026-07-30 20:05 EST

Merit Medical Reports Second Quarter 2026 Results And Updates Full-Year 2026 Guidance

STIMNeuronetics2026-07-28 12:30 EST

Neuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call

DNLIDenali Therapeutics2026-07-27 20:01 EST

Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026

CVRXCVRx2026-07-23 20:30 EST

CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026

AORTArtivion2026-07-23 20:10 EST

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results

View all latest news

Pulse Biosciences

Nanosecond Pulsed-Field Ablation Pulse Biosciences develops the nPulse platform, which delivers proprietary nanosecond pulsed-field energy to ablate targeted tissue. The technology is designed to create nonthermal cellular effects and is being evaluated in cardiac and soft-tissue applications. Cardiac Catheter System The nPulse Cardiac...

Recent company news

PLSEPulse Biosciences2026-08-06 20:05 EST

Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results

PLSEPulse Biosciences2026-07-30 20:05 EST

Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference

PLSEPulse Biosciences2026-07-29 11:00 EST

Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study

PLSEPulse Biosciences2026-07-21 20:05 EST

Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026

PLSEPulse Biosciences2026-07-15 20:05 EST

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
38.24 USD
Market cap
1.68B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States